Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edwards Lifesciences (NY: EW )

72.07 +0.52 (+0.73%)
Official Closing Price Updated: 7:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edwards Lifesciences

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Benzinga's Top Ratings Upgrades, Downgrades For February 6, 2023
Via Benzinga
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 4
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of Jan. 30 through Feb. 3. 
Via Talk Markets
Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023
Via Benzinga
Edwards Lifesciences Stock Jumps After Beating Fourth-Quarter Views
The company expects full-year sales to grow 9%-12% in constant currency. 
Via Investor's Business Daily
Here's How Much $1000 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today
Via Benzinga
What 8 Analyst Ratings Have To Say About Edwards Lifesciences
Via Benzinga
2 Top Dividend Growth Stocks to Buy in February
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace. 
Via The Motley Fool
Earnings Scheduled For January 31, 2023
Companies Reporting Before The Bell • Biophytis (NASDAQ:BPTS) is projected to report earnings for its first quarter. 
Via Benzinga
A Preview Of Edwards Lifesciences's Earnings
Via Benzinga
Expert Ratings for Edwards Lifesciences
Via Benzinga
15 Analysts Have This to Say About Edwards Lifesciences
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
Amazon To Rally Around 29%? Here Are 10 Other Analyst Forecasts For Monday
Barclays cut the price target for Amazon.com, Inc. (NASDAQ: AMZN) from $140 to $130. Barclays analyst Ross Sandler maintained an Overweight rating. Amazon shares fell 1.2% to $101.06 in pre-market... 
Via Benzinga
Why Edwards Lifesciences Stock Crashed 16% Today
Did investors overreact to the company's miss? 
Via The Motley Fool
2 Smartest Tech Stocks to Buy in 2022 and Beyond
The tech space is still bursting with opportunities for long-term investors. 
Via The Motley Fool
Jim Cramer Recommends These 5 Healthcare Stocks For 2023: 'Biggest Winners Were Boring, Consistent Operators'
Prominent market commentator Jim Cramer has recommended five healthcare stocks which he believes should be on investors’ shopping list for 2023. 
Via Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
S&P 500 Component DexCom Set For Further Price, Earnings Growth
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For December 2, 2022
Via Benzinga
Edwards Life Sciences Stock Disaster Could Be Your Bounty
Heart disease equipment maker Edwards Life Sciences (NYSE: EW) stock has fallen (-46%) on the year after a disastrous reaction to its Q3 2022 earnings report. 
Via MarketBeat
Topics Death
Exposures COVID-19 Death
Cramer's Take On This Stock That's Down 53% Year-To-Date: 'I Think Long-Term. I Don't Want To Own It'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cerence Inc. (NASDAQ: CRNC) can fall to $13, $12 in a market like this. "If you can take that level of pain, you can absolutely buy it, because it... 
Via Benzinga
7 Stocks to Buy at the ‘Midterm Elections’ Bottom
With the market tending to react positively to midterm election cycles, now may be a time to consider certain stocks to buy. 
Via InvestorPlace
Honeywell To $194? Plus Citigroup Slashes PT On This Stock By Over 93%
  Daiwa Capital slashed the price target on Honeywell International Inc. (NYSE: HON) from $206 to $194. Honeywell shares fell 0.6% to $203.79 in pre-market trading. 
Via Benzinga
Weibo, XPeng, Li Auto And Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 800 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
Via Benzinga
Nasdaq Climbs 275 Points; S&P 500 Rises Over 2%
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite surging more than 200 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 5 years by 7.47% on an annualized basis producing an average annual return of 15.86%. Currently, Edwards Lifesciences has a... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.